Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by LGT Group Foundation

LGT Group Foundation grew its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 68.7% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 4,620 shares of the pharmaceutical company’s stock after buying an additional 1,881 shares during the quarter. LGT Group Foundation’s holdings in Vertex Pharmaceuticals were worth $1,867,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Chesapeake Asset Management LLC raised its position in shares of Vertex Pharmaceuticals by 110.0% in the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock worth $25,000 after buying an additional 33 shares during the period. Colonial Trust Co SC grew its position in Vertex Pharmaceuticals by 118.8% during the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 38 shares during the period. Total Investment Management Inc. acquired a new stake in Vertex Pharmaceuticals during the second quarter worth about $33,000. Financial Network Wealth Advisors LLC increased its stake in Vertex Pharmaceuticals by 50.9% during the third quarter. Financial Network Wealth Advisors LLC now owns 86 shares of the pharmaceutical company’s stock worth $34,000 after acquiring an additional 29 shares during the last quarter. Finally, Y.D. More Investments Ltd raised its holdings in shares of Vertex Pharmaceuticals by 345.0% in the 3rd quarter. Y.D. More Investments Ltd now owns 89 shares of the pharmaceutical company’s stock worth $35,000 after purchasing an additional 69 shares during the period. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock opened at $460.87 on Tuesday. The firm has a market capitalization of $117.07 billion, a PE ratio of 30.06 and a beta of 0.31. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $519.68. The stock’s 50 day moving average price is $467.50 and its 200 day moving average price is $435.79.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The firm had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.18 billion. During the same period in the previous year, the business posted $3.98 earnings per share. Vertex Pharmaceuticals’s revenue for the quarter was up 9.5% on a year-over-year basis. On average, analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, EVP Charles F. Wagner, Jr. sold 9,532 shares of the firm’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $461.00, for a total transaction of $4,394,252.00. Following the transaction, the executive vice president directly owned 37,725 shares in the company, valued at $17,391,225. This trade represents a 20.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Mark E. Bunnage sold 2,021 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total transaction of $930,529.03. Following the completion of the transaction, the executive vice president directly owned 12,914 shares of the company’s stock, valued at approximately $5,945,993.02. This represents a 13.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 91,156 shares of company stock valued at $42,845,497. Corporate insiders own 0.20% of the company’s stock.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: RAINIER interim results: The company said a pre‑specified Week‑36 interim analysis of the Phase 3 RAINIER trial of povetacicept met the primary objective and all secondary endpoints, citing meaningful efficacy vs. placebo in adults with IgA nephropathy — the core catalyst driving the move. Business Wire release
• Positive Sentiment: Analyst reinforcement: William Blair’s Myles Minter reiterated a Buy and said confidence in povetacicept’s profile has increased after the RAINIER readout, strengthening the bullish investment case for VRTX. Analyst backing amplifies the positive reaction. TipRanks/William Blair note
• Positive Sentiment: Perception of high commercial potential: Coverage notes that povetacicept — acquired in a multibillion‑dollar deal — could be a best‑in‑class therapy in a competitive kidney disease market, supporting a longer‑term revenue upside if full data and approvals follow. BioPharmaDive article
• Neutral Sentiment: Market reaction and headlines: Media and trading outlets reported a sharp after‑hours/share surge following the announcement; that immediate momentum reflects sentiment but may be volatile as investors digest details and next steps. Benzinga coverage
• Negative Sentiment: Ongoing uncertainty: These are interim results from an ongoing trial — final RAINIER readout, safety follow‑up, regulatory timelines and payer/commercial execution remain unknown. Investors should weigh upside against the risk that final data or regulatory review could change the outlook. Yahoo Finance release

Wall Street Analyst Weigh In

VRTX has been the subject of a number of research reports. Oppenheimer upgraded Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $540.00 target price for the company in a report on Friday, February 13th. Leerink Partners raised their price target on shares of Vertex Pharmaceuticals from $456.00 to $525.00 and gave the company an “outperform” rating in a report on Monday, December 29th. Stifel Nicolaus lifted their price target on shares of Vertex Pharmaceuticals from $445.00 to $466.00 and gave the company a “hold” rating in a research report on Friday, February 13th. Scotiabank boosted their price objective on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the stock an “outperform” rating in a research note on Friday, February 13th. Finally, Wells Fargo & Company increased their price objective on shares of Vertex Pharmaceuticals from $460.00 to $515.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Twenty-two investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $542.00.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.